🔒

Granted Patent — Foundational IP

OncoBayes holds a granted patent on the world's first bioavailable oral formulation of Elacridar — the only P-gp/BCRP dual inhibitor capable of chronic oral co-dosing. Patent family covers formulation composition, method-of-use, and co-administration regimen. Exclusivity extends beyond 2041.

No equivalent rights exist in the public domain · No competitor holds freedom-to-operate · The only path to an oral BBB-penetrant combination product runs through OncoBayes

Partnership Proposal

Verzenio works.
It just can't reach 30% of your patients. We hold the only patented solution — and we'd rather build it with you.

OncoBayes was founded with one mission: to solve drug delivery across the blood-brain barrier in cancer. We have done that. The most valuable immediate application of what we built is sitting inside your own portfolio.

60^×

Abemaciclib M20
brain penetration uplift

The magnitude of P-gp/BCRP-mediated CNS exclusion for abemaciclib's most active metabolite — confirmed in knockout mouse models. Elacridar co-administration fully replicates the knockout phenotype in wild-type animals.

Our patented oral formulation delivers this effect as a once-daily tablet at well-tolerated doses, suitable for chronic co-administration. This is the clinical transformation waiting to be unlocked in your $5.7B drug — by the only company that holds the IP to make it possible.

The Problem You Know

~30% of HR+/HER2− metastatic breast cancer patients develop brain metastases. When they do, Verzenio delivers an intracranial ORR of just 6%. Not because abemaciclib is inactive in the brain — Phase 1 CSF data confirms it gets there — but because P-gp and BCRP at the blood-brain barrier are actively ejecting it before it reaches therapeutic concentrations. This is a transporter problem. It is solvable. And it is currently costing those patients their best chance — and costing Lilly a blockbuster-sized indication.

The Solution We Patented

Elacridar is the gold-standard dual P-gp/BCRP inhibitor, with a clean Phase I safety profile alongside topotecan and doxorubicin. Its clinical potential was never realised for one reason: its own oral absorption was so poor that chronic dosing was impossible. We solved that problem. Our patented lipid nanoparticle platform achieves sustained systemic elacridar exposure sufficient to inhibit BBB transporters — orally, once daily, without dose-limiting toxicity. This IP is granted, protected, and exclusively ours.

What This Unlocks for Lilly

A Verzenio + OncoBayes-elacridar combination for breast cancer brain metastases would be the first CDK4/6 inhibitor approved for this indication — a new label, a new pricing tier, and a franchise defence against the 2033 generic cliff. Based on knockout data and our Phase I PK, we project intracranial ORR could improve from 6% to 25–40%, the kind of signal that generates Breakthrough Designation, accelerated approval, and an entirely new commercial chapter for Verzenio.

$5.7B

Verzenio FY2025
worldwide revenue

~30%

MBC patients who
develop brain mets

2033

Verzenio core
patent LOE

2041+

OncoBayes elacridar
patent exclusivity

Why Partner Now

The arithmetic is unambiguous.
The window is not.

Verzenio's core LOE is 2033. A combination product requires 6–8 years of development. A partnership decision in 2026 is the last opportunity to launch a Verzenio BCBM combination under your commercial infrastructure — with your oncologist relationships, your trial infrastructure, and your brand equity fully intact. Miss this window and any programme initiated later launches into a genericised market, without our IP, without the head start you could have today.

OncoBayes is in active discussions with other oncology companies regarding our platform applied to selpercatinib (Retevmo) and next-generation KRAS inhibitor programmes. The opportunity to co-develop the abemaciclib combination on exclusive terms is time-limited. We are raising this with Lilly first because abemaciclib is the highest-value application of our technology — and because we believe Lilly is the right partner to see it through.

Proposed Partnership Structure

→ Lilly funds Phase 1b/2 in BCBM (CSF PK primary endpoint); OncoBayes provides formulation, IP licence, and scientific leadership throughout development
→ OncoBayes retains manufacturing rights to the bioavailable elacridar component; Lilly leads commercialisation of the combination product globally
→ Milestone payments: upfront licence access + Phase 1b data readout + Phase 3 initiation + regulatory approval triggers across major markets
→ Mid-single-digit royalty on worldwide combination net sales; Lilly's standalone Verzenio rights remain entirely unaffected
→ Right of first negotiation to licence OncoBayes platform for Retevmo and imlunestrant at pre-agreed discounted terms
→ Joint method-of-use and dosing-regimen patents co-filed immediately — protecting both parties through 2040+

⚠

On freedom-to-operate: OncoBayes's granted patent covers the bioavailable elacridar formulation comprehensively. There is no FTO for any party — including Lilly — to develop a chronic oral elacridar co-therapy independently without an OncoBayes licence. Any BCBM programme built on P-gp/BCRP inhibition will require either our IP, or a significantly inferior IV elacridar approach. We are offering co-development. The alternative is a protracted licensing negotiation from a position of clinical urgency — or a less competitive clinical programme.

"You built one of the most successful oncology franchises of the decade. We built the only patented key to unlock the one sanctuary where it currently fails. Together, we give the 30% of breast cancer patients abandoned by Verzenio at the blood-brain barrier a genuine chance — and we extend your franchise by nearly a decade beyond the patent cliff."

Request a Scientific Briefing

info@oncobayes.com

oncobayes.com

Verzenio works. It just can't reach 30% of your patients. We hold the only patented solution — and we'd rather build it with you.

Verzenio works.
It just can't reach 30% of your patients. We hold the only patented solution — and we'd rather build it with you.